CurrentBlue KCPolicy POL-PP-286 / AHS - M2116

Human Immunodeficiency Virus (HIV)

Defines reimbursement/coverage criteria for HIV screening, diagnostic, nucleic acid testing, genotyping/phenotyping, viral quantification, and excluded/limited tests across Blue KC lines of business. Applies to testing frequency, indications (age, risk, pregnancy, PrEP), and specific CPT/HCPCS codes.

Policy Summary

PayerBlue KC

PolicyHuman Immunodeficiency Virus (HIV)

Policy CodePolicy POL-PP-286 / AHS - M2116

Change TypeVersion 002 (Avalon 4 Quarter updates)

Effective DateOct 1, 2025

Next Review DateOct 1, 2026

Key ActionConfirm member eligibility and benefit limits prior to testing.

SourceLink

POLICY UPDATE CHANGES

Version 001 created on 07/01/2025 (initial version).

Version 002 effective 10/01/2025 (Avalon 4 Quarter updates).

11-65Screening Age Range

Frequency limitsRepeat Testing Limits

Certain coveredGenotype/Phenotype

3 exclusionsNot Covered Items

Scope: This policy defines reimbursement and coverage criteria for HIV testing across screening, diagnostic confirmation, nucleic acid testing (detection and quantification), genotyping/phenotyping (drug resistance testing), and specific exclusions/limitations. It applies to testing frequency, indications (age, risk, pregnancy, PrEP), and specified CPT/HCPCS codes across Blue KC lines of business.

Overview: Coverage stance is mixed. Effective date: 10/01/2025; Last review: 10/01/2025; Next review due: 10/01/2026. The policy addresses screening (including rapid and oral tests), diagnostic follow-up (antibody differentiation and nucleic acid testing), NAT/quantification (HIV-1 and HIV-2 RNA), genotyping/phenotyping (with some situations covered and some methods limited), and explicit exclusions (e.g., standalone antigen testing, routine combined genotyping/phenotyping, and certain predictive bioinformatics).

Surface thresholds and quick facts

Antibody/antigen testing frequencyNot more often than once every 90 days

Nucleic acid testing frequencyNot more often than once every month

Screening Age RangeCovered: individuals 11 to 65 years of age

Repeat Testing LimitsRepeat screening may be reimbursed but subject to Note 1 frequency limits

Genotype/Phenotype CoverageCertain genotyping/phenotyping reimbursed (e.g., prior to doravirine, treatment failure, pregnancy-related indications)

Explicit Not Covered ItemsHIV antigen testing alone; routine combined genotyping+phenotyping; drug-susceptibility prediction via genotypic database — not reimbursed

Medical-necessity criteria

General Screening

Covered when ALL of the following are met:

ALL of the following

Individual is 11 to 65 years of age
Initial screening may be reimbursed

Repeat Screening

Covered when ALL of the following are met:

ALL of the following

Individual is 11 to 65 years of age
Repeat screening may be reimbursed (see Note 1 for frequency limits)

Screening for Individuals on or Considering PrEP or at Elevated Risk

Covered when ANY of the following risk conditions apply:

ANY of the following

Individual will begin pre-exposure prophylaxis (PrEP)
Individual is receiving PrEP
Individual has elevated risk factors for HIV infection (see Note 2)
Screening method: antigen/antibody combination assay or rapid antibody test
May be reimbursed

Positive Initial Screening - Follow-up Testing

Covered when ANY of the following are met after a positive/indeterminate initial screen:

ANY of the following

HIV-1/HIV-2 antibody differentiation assay may be reimbursed for individuals with positive initial screening
Nucleic Acid Testing (qualitative or quantitative) for HIV-1 and HIV-2 may be reimbursed for individuals with positive initial screening
Nucleic Acid Testing (qualitative or quantitative) may be reimbursed for individuals with indeterminate initial screening
Nucleic Acid Testing (qualitative or quantitative) may be reimbursed for individuals with suspected or reported recent exposure

HIV Genotyping / Phenotyping

Genotyping/phenotyping may be reimbursed in ANY of the following situations:

ANY of the following

Prior to initiating doravirine therapy (genotyping and phenotyping is required)
Required prior to doravirine initiation
Individuals who have failed a course of antiviral therapy
Individuals who have suboptimal viral load reduction
Individuals who have been noncompliant with therapy
To guide treatment decisions in individuals with acute or recent infection (within the last 6 months)

Baseline HIV Quantification

Covered when ANY of the following baseline conditions are present and initiation of therapy is anticipated:

ANY of the following

At-risk individual with persistence of borderline or equivocal serologic reactivity
At-risk individual with signs and symptoms of acute retroviral syndrome (fever, malaise, lymphadenopathy, rash)

Not Covered / Limited

The following do NOT meet coverage criteria:

ALL of the following

HIV antigen testing independent of antigen/antibody testing
Not reimbursed due to lack of evidence
Routine use of combined genotyping and phenotyping
Not reimbursed
Drug susceptibility phenotype prediction using genotypic comparison to known genotypic/phenotypic database
Not reimbursed

Coding

Antibody tests / ConfirmatoryCPTCovered

86689	Antibody; HTLV or HIV antibody, confirmatory test (e.g., Western Blot)
86701	Antibody; HIV-1
86702	Antibody; HIV-2
86703	Antibody; HIV-1 and HIV-2, single result

Antigen/Antibody combination and antigen assaysCPTCovered

87389	HIV-1 antigen(s) with HIV-1 and HIV-2 antibodies, single result (combination assay)
87390	HIV-1 antigen
87391	HIV-2 antigen
G0475	HIV antigen/antibody, combination assay, screening

Rapid antibody / Oral testing (screening)CPT/HCPCSCovered

G0432	Antibody detection by EIA, HIV-1 and/or HIV-2, screening
G0433	Antibody detection by ELISA, HIV-1 and/or HIV-2, screening
G0435	Rapid antibody test, HIV-1 and/or HIV-2, screening
S3645	HIV-1 antibody testing of oral mucosal transudate

Nucleic acid tests (detection / quantification)CPTCovered

87534	Infectious agent detection by nucleic acid; HIV-1, direct probe technique
87535	HIV-1, amplified probe technique, includes reverse transcription when performed
87536	HIV-1, quantification, includes reverse transcription when performed
87537	HIV-2, direct probe technique
87538	HIV-2, amplified probe technique, includes reverse transcription when performed
87539	HIV-2, quantification, includes reverse transcription when performed

Rapid/visual antigen assaysCPTCovered

87806

Infectious agent antigen detection by immunoassay with direct optical observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies

Genotype / Phenotype / Drug susceptibilitymixed

87900	Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics (not reimbursed per policy)
87901	Infectious agent genotype analysis by nucleic acid; HIV-1, reverse transcriptase and protease regions
87903	Infectious agent phenotype analysis with drug resistance tissue culture analysis, HIV-1; first through 10 drugs tested
87904	Infectious agent phenotype analysis, each additional drug tested
87906	Infectious agent genotype analysis; HIV-1, other region (e.g., integrase, fusion)
0219U	Targeted viral NGS analysis (protease, RT, integrase), algorithm reported as prediction of antiviral drug susceptibility (Sentosa® SQ HIV-1 Genotyping Assay) - proprietary

Medicare screening codesHCPCSCovered

G0432	Antibody detection by EIA, HIV-1 and/or HIV-2, screening
G0433	Antibody detection by ELISA, HIV-1 and/or HIV-2, screening
G0435	Rapid antibody test, HIV-1 and/or HIV-2, screening
G0475	HIV antigen/antibody, combination assay, screening

Provider actions & billing impact

Documentation Required

Confirm benefit coverage and medical necessity

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request; providers should confirm member eligibility and benefit limits prior to testing.

Documentation Required

Adhere to testing frequency limits

Do not repeat antibody/antigen testing more often than once every 90 days and do not repeat nucleic acid testing more often than once every month (Note 1).

Antibody/antigen testing: Not more often than once every 90 days
Nucleic acid testing (qualitative or quantitative): Not more often than once every month

Prior Authorization

Genotype/phenotype prior to doravirine

Genotyping and phenotyping are required prior to initiating doravirine therapy; ensure tests are obtained and documented before starting doravirine.

Billing Rule

Use consistent assay for serial HIV RNA measurements

Because differences in absolute HIV copy number are known to occur using different assays, plasma HIV RNA levels should be measured by the same analytical method. If the assay method is changed, a re-establishment of baseline may be necessary.

Changing assay may require re-establishment of baseline HIV RNA measurements

Background and clinical context

Background: Human immunodeficiency virus (HIV) is an RNA retrovirus that infects CD4 immune cells leading to progressive immune deterioration and risk of opportunistic infections and HIV-related malignancies. The policy notes that HIV-1 is the dominant subtype while HIV-2 remains important in certain regions such as Western Africa, and that testing is applied across clinical contexts including screening, pre-exposure prophylaxis (PrEP) initiation and monitoring, pregnancy-related testing, evaluation of acute infection, and assessment of treatment failure or antiviral resistance.

The policy references CDC and other clinical resources in describing HIV biology and test indications and specifies reimbursement approaches for initial and repeat screening, confirmatory antibody differentiation, nucleic acid testing for suspected or confirmed infection, baseline and monitoring quantification, and genotyping/phenotyping for guiding therapy or evaluating treatment failure.

Definitions / Notes

Note 1 - testing intervalsAntibody and antibody/antigen testing should not be repeated more often than once every 90 days; nucleic acid testing should not be repeated more often than once every month.

Note 2 - risk factors listRisk factors include: MSM, MSM-W, transgender status; sexual encounter with known HIV-positive person; multiple partners since last test; sharing injection equipment; exchanging sex for money/drugs; prior or concurrent STI/hepatitis/tuberculosis; partner with unknown/high-risk history.

Note 3 - RNA measurement consistencyPlasma HIV RNA levels should be measured by the same analytical method because absolute copy number differences can occur between assays; changing assay may require re-establishment of baseline.

OpenPayer

Human Immunodeficiency Virus (HIV)

Coverage summary

Medical-necessity criteria

Coding

Provider actions & billing impact

Background and clinical context

Revision history